MedPath

Life Molecular Imaging GmbH

🇩🇪Germany
Ownership
-
Established
2011-01-01
Employees
-
Market Cap
-
Website
http://www.mdpi.com/journal/life

Clinical Trials

4

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:3
Phase 3:1

Drug Approvals

3

EMA:2
CIMA_AEMPS:1

Drug Approvals

Neuraceq

Authorization Status
Authorised
Approval Date
Feb 20, 2014
EMA

Neuraceq

Authorization Status
Authorised
Approval Date
Feb 20, 2014
EMA

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 3
1 (25.0%)

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

Phase 1
Not yet recruiting
Conditions
Cardiac Amyloidosis
Interventions
First Posted Date
2025-01-24
Last Posted Date
2025-05-15
Lead Sponsor
Life Molecular Imaging GmbH
Target Recruit Count
15
Registration Number
NCT06790394
Locations
🇬🇧

Royal Free Hospital, London, United Kingdom

🇬🇧

King's College London, London, United Kingdom

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

Phase 1
Completed
Conditions
Progressive Supranuclear Palsy
Interventions
Drug: [18F]-PI2620
First Posted Date
2022-01-12
Last Posted Date
2025-05-18
Lead Sponsor
Life Molecular Imaging GmbH
Target Recruit Count
15
Registration Number
NCT05187546
Locations
🇩🇪

Ludwig-Maximilians-Universität München, Munich, Germany

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Phase 3
Recruiting
Conditions
Cardiac Amyloidosis
AL Amyloidosis
ATTR Amyloidosis
Interventions
Drug: [18F]florbetaben
First Posted Date
2022-01-11
Last Posted Date
2025-06-26
Lead Sponsor
Life Molecular Imaging GmbH
Target Recruit Count
200
Registration Number
NCT05184088
Locations
🇺🇸

St Luke's Hospital, Kansas City, Kansas, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 11 locations

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

Phase 1
Completed
Conditions
Progressive Supranuclear Palsy
Alzheimer Disease
Interventions
Drug: [18F]-PI2620
First Posted Date
2021-01-20
Last Posted Date
2025-05-18
Lead Sponsor
Life Molecular Imaging GmbH
Target Recruit Count
10
Registration Number
NCT04715750
Locations
🇩🇪

Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.